Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis

Norum, Jan; Olsen, Jan Abel; Wist, Erik; Lønning, Per Eystein

doi:10.1080/02841860601096841

Cited by 46 publications

(53 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Trastuzumab adjuvant treatment for early HER-2 positive breast cancer is effective for improving patient survival and cost-effectiveness analyses of such treatment have shown acceptable ratios (Fagnani et al, 2007;Garrison et al, 2007;Millar and Millward, 2007;Norum et al, 2007). However, there is a negative aspect to trastuzumab therapy, namely cardiac toxicity (Wolff et al, 2007), which is possibly due to myocardial HER-2 gene over-expression associated with anthracycline treatment (De Korte et al, 2007) and substantial trastuzumab therapy 330 costs.…”

Section: Erbb2/her-2 (Her-2/neu Neu Ngl Her-2 Tkr1 Cd340mentioning

confidence: 99%

Efficacy of Primed In Situ Labelling in Determination of HER-2 Gene Amplification and CEN-17 Status in Breast Cancer Tissue

Salimi

Mozdarani²,

Majidzadeh‐A³

2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Erbb2/her-2 (Her-2/neu Neu Ngl Her-2 Tkr1 Cd340mentioning

confidence: 99%

Efficacy of Primed In Situ Labelling in Determination of HER-2 Gene Amplification and CEN-17 Status in Breast Cancer Tissue

Salimi

Mozdarani²,

Majidzadeh‐A³

2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…With respect to lost production, for example, as it is in general easier to calculate time off work during treatment, compared to the potential opportunity cost of future production, most studies scrutinized the former issue and made no reference to the latter. How appropriate this approach is, is open to debate [40]. Finally, unit cost is another crucial factor to take into account when trying to interpret cost effectiveness study.…”

Section: Study Perspectivementioning

confidence: 99%

“…Trastuzumab is expensive, for instance in the UK, to prevent one recurrent case, the estimated cost was £400,000 [39] while in other countries, one year's treatment per patient could cost between $US60,000 and $Cdn35,000 to 45,000 [40] (equivalent to $42,490 to $54,630, PPP=1.214-2015) [41]. Its use as an adjuvant chemotherapy has been promising, with it being added in the recently updated Model List of Essential Medicine of WHO [42] despite its expense [40,43].…”

Section: Health Economic Evaluation Of Trastuzumab In the Treatment Omentioning

confidence: 99%

“…Its use as an adjuvant chemotherapy has been promising, with it being added in the recently updated Model List of Essential Medicine of WHO [42] despite its expense [40,43]. In fact, it is publicly funded in all Western European and most of Eastern European countries, resulting in significant financial burden on the healthcare system [43].…”

Section: Health Economic Evaluation Of Trastuzumab In the Treatment Omentioning

confidence: 99%

“…This decision likely reflected access to data, details of resource use and reimbursements by third party payers being generally more readily available than details of out of pocket expenditures or where costs relate to absenteeism or presenteeism. In studies adopting a societal perspectives, many included this as part of an analysis undertaken from the payer's perspective [40,56,57]. From the payer's perspective, most studies included as costs HER-2 testing, drug acquisition and drug administration costs, as well as supportive medications [47,54,55], cardiac monitoring [47,55], costs of palliative Trastuzumab [51,54,55], cost of local and distant cancer recurrences [47,51,54,55] as well as the cost of different chemotherapy-related adverse events [47].…”

Section: Study Perspectivementioning

confidence: 99%

See 2 more Smart Citations

A Critical Review of Economic Evaluations of Trastuzumab in the Treatment of Early Stage HER2 Positive Breast Cancer

Nguyen¹,

Nguyen²,

O'Neill³

2017

Pharmacoeconomics

View full text Add to dashboard Cite

Eleven years after Trastuzumab was approved for use in the treatment of early stage human epidermal growth factor receptor positive breast cancer (HER2+) its clinical benefit has been demonstrated in short and long term follow up studies. The cost-effectiveness of the therapy in this context remains the subject of debate with a wide range of Incremental Cost Effectiveness Ratios (ICERs) reported in the literature. While several reviews of the literature have been undertaken these have not provided a critical analysis of the factors that might underlie this heterogeneity. In this review we provide a critical overview of the literature and discuss potential sources of heterogeneity in reported ICERs. We identify gaps in the current literature and provide a rationale for filling these gaps.

show abstract

Cost‐effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2‐positive breast cancer

Garrison

Lubeck

Lalla

et al. 2007

Cancer

107

View full text Add to dashboard Cite

BACKGROUND.Adding trastuzumab to adjuvant chemotherapy provides significant clinical benefit in patients with human epidermal growth factor receptor 2 (HER2)‐positive breast cancer. A cost‐effectiveness analysis was performed to assess clinical and economic implications of adding trastuzumab to adjuvant chemotherapy, based upon joint analysis of NSABP B‐31 and NCCTG N9831 trials.METHODS.A Markov model with 4 health states was used to estimate the cost utility for a 50‐year‐old woman on the basis of trial results through 4 years and estimates of long‐term recurrence and death based on a meta‐analysis of trials. From 6 years onward, rates of recurrence and death were assumed to be the same in both trastuzumab and chemotherapy‐only arms. Incremental costs were estimated for diagnostic and treatment‐related costs. Analyses were from payer and societal perspectives, and these analyses were projected to lifetime and 20‐year horizons.RESULTS.Over a lifetime, the projected cost of trastuzumab per quality‐adjusted life year (QALY; discount rate 3%) gained was $26,417 (range, $9104‐$69,340 under multiway sensitivity analysis). Discounted incremental lifetime cost was $44,923, and projected life expectancy was 3 years longer for patients who received trastuzumab (19.4 years vs 16.4 years). During a 20‐year horizon, the projected cost of adding trastuzumab to chemotherapy was $34,201 per QALY gained. Key cost‐effectiveness drivers were discount rate, trastuzumab price, and probability of metastasis. The cost‐effectiveness result was robust to sensitivity analysis.CONCLUSIONS.Trastuzumab for adjuvant treatment of early stage breast cancer was projected to be cost effective over a lifetime horizon, achieving a cost‐effectiveness ratio below that of many widely accepted oncology treatments. Cancer 2007. © 2007 American Cancer Society.

show abstract

Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis

Cited by 46 publications

References 34 publications

Efficacy of Primed In Situ Labelling in Determination of HER-2 Gene Amplification and CEN-17 Status in Breast Cancer Tissue

Efficacy of Primed In Situ Labelling in Determination of HER-2 Gene Amplification and CEN-17 Status in Breast Cancer Tissue

A Critical Review of Economic Evaluations of Trastuzumab in the Treatment of Early Stage HER2 Positive Breast Cancer

Cost‐effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2‐positive breast cancer

Contact Info

Product

Resources

About